EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Resistance to targeted therapies in acute myeloid leukemia

Rabea Mecklenbrauck, Michael Heuser

Clinical & Experimental Metastasis · 2023-02 · 40 (1) · 33-44

DOI: 10.1007/s10585-022-10189-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Metastasis, online erschienen am 01.11.2022. Verfasst von Rabea Mecklenbrauck und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of new targeted therapies to the treatment algorithm of acute myeloid leukemia (AML) offers new opportunities, but also presents new challenges. Patients diagnosed with AML receiving targeted therapies as part of lower intensity regimens will relapse inevitably due to primary or secondary resistance mechanisms. In this review, we summarize the current knowledge on the main mechanisms of resistance to targeted therapies in AML. Resistance to FLT3 inhibitors is mainly mediated by on target mutations and dysregulation of downstream pathways. Switching the FLT3 inhibitor has a potential therapeutic benefit. During treatment with IDH inhibitors resistance can develop due to aberrant cell metabolism or secondary site IDH mutations. As a unique resistance mechanism the mutated IDH isotype may switch from IDH1 to IDH2 or vice versa. Resistance to gemtuzumab-ozogamicin is determined by the CD33 isotype and the degradation of the cytotoxin. The main mechanisms of resistance to venetoclax are the dysregulation of alternative pathways especially the upregulation of the BCL-2-analogues MCL-1 and BCL-XL or the induction of an aberrant cell metabolism. The introduction of therapies targeting immune processes will lead to new forms of therapy resistance. Knowing those mechanisms will help to develop strategies that can overcome resistance to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansGemtuzumabProtein Kinase InhibitorsMutation

Stichwörter der Autor:innen

FLT3 inhibitorsGemtuzumab-ozogamicinIDH inhibitorsPrimary resistanceVenetoclax

Substanzen

GemtuzumabProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
  • Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. heuser.michael@mh-hannover.de.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Mecklenbrauck, R., & Heuser, M. (2023). Resistance to targeted therapies in acute myeloid leukemia. Clinical & Experimental Metastasis, 40(1), 33-44. https://doi.org/10.1007/s10585-022-10189-0

Vancouver

Mecklenbrauck R, Heuser M. Resistance to targeted therapies in acute myeloid leukemia. Clinical & Experimental Metastasis. 2023;40(1):33-44. doi:10.1007/s10585-022-10189-0

BibTeX
@article{Mecklenbrauck2023,
  author = {Mecklenbrauck, Rabea and Heuser, Michael},
  title = {Resistance to targeted therapies in acute myeloid leukemia},
  journal = {Clinical & Experimental Metastasis},
  year = {2023},
  volume = {40},
  number = {1},
  pages = {33--44},
  doi = {10.1007/s10585-022-10189-0}
}
Kostenlos starten →